* Mark Waugh appointed new CEO* Relevant background from orthapaedic industry* Supportive for sentiment Getting ready for the next phase OssDsign has appointed Mark Waugh as its new CEO, effective 1 January 2026. Waugh joins from Medacta USA, where he served as SVP Commercial, and brings 20+ years of commercial and leadership experience across major ortho companies including Smith & Nephew and Medtronic with a focus on commercial execution and US expansion in spine and broader orthopaedics. Mark Waugh will start on 1 January 2026, and be based in the US. Outgoing CEO Morten Henneveld leaves after five years in which OssDsign has transformed its business and delivered strong double-digit growth, driven by the US launch of Catalyst in 2021. Relevant background We believe Mark Waugh to have a very relevant background with solid credentials to take OssDsign to the next level, after a successful launch in the US market. The focus will be to accelerate the commercialisation of Catalyst by deepen U.S. market penetration, and continue scaling surgeon and distributor adoption. Positive for sentiment The appointment of a new CEO should help to support the share price sentiment in OssDsign. We believe it is positive that the Board of Directors has found a new CEO with relevant background from industry, based in the US, to take the company to the next level. We leave our estimates unchanged and reiterate our fair value range unchanged at SEK 10-17